Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort

BACKGROUND: There is currently no standard second-line treatment for metastatic pancreatic adenocarcinoma (MPA), and progression-free survival is consistently <4 months in this setting. The aim of this study was to evaluate the efficacy and tolerability of Nab-paclitaxel plus gemcitabine (A+G) af...

Descripción completa

Detalles Bibliográficos
Autores principales: Portal, Alix, Pernot, Simon, Tougeron, David, Arbaud, Claire, Bidault, Anne Thirot, de la Fouchardière, Christelle, Hammel, Pascal, Lecomte, Thierry, Dréanic, Johann, Coriat, Romain, Bachet, Jean-Baptiste, Dubreuil, Olivier, Marthey, Lysiane, Dahan, Laetitia, Tchoundjeu, Belinda, Locher, Christophe, Lepère, Céline, Bonnetain, Franck, Taieb, Julien
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4651133/
https://www.ncbi.nlm.nih.gov/pubmed/26372701
http://dx.doi.org/10.1038/bjc.2015.328

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4651133/
https://www.ncbi.nlm.nih.gov/pubmed/26372701
http://dx.doi.org/10.1038/bjc.2015.328

Ejemplares similares